The Gulf Time Newspaper One of the finest business newspapers in the UAE brought to you by our professional writers and editors.
Bloomberg
Pfizer Inc is in advanced talks to buy Global Blood Therapeutics Inc., the maker of a therapy for sickle-cell disease, for about $5 billion, the Wall Street Journal (WSJ) reported.
The New York-based drug giant is looking to finalise a deal in the coming days, the Journal reported. Bloomberg News had reported earlier this week that biotech was drawing takeover interest from large pharmaceutical companies.
Global Blood’s Oxbryta is approved by the US Food and Drug Administration to treat sickle-cell, a hard-to-treat, painful disease that most commonly affects Black people.
Pfizer representatives didn’t immediately respond to a request for comment. A spokesman for South San Francisco, California-based Global Blood said the company doesn’t comment on market rumours or speculation.